- Home
- ARMK vs MDGL Comparison
ARMK vs MDGL Comparison
Compare ARMK & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARMK | MDGL |
|---|---|---|
| Founded | 1959 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3B | 12.8B |
| IPO Year | 2013 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ARMK | MDGL |
|---|---|---|
| Price | $59.77 | $516.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $47.88 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 2.5M | 370.1K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.07% | N/A |
| EPS Growth | ★ 23.23 | N/A |
| EPS | ★ 1.11 | N/A |
| Revenue | ★ $18,506,299,000.00 | $180,133,000.00 |
| Revenue This Year | $8.71 | $58.39 |
| Revenue Next Year | $6.57 | $48.55 |
| P/E Ratio | $53.49 | ★ N/A |
| Revenue Growth | ★ 6.35 | N/A |
| 52 Week Low | $35.07 | $393.61 |
| 52 Week High | $62.65 | $615.00 |
Technical Indicators
Market Signals| Indicator | ARMK | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 56.46 | 48.58 |
| Support Level | $55.19 | $497.85 |
| Resistance Level | $62.65 | $545.13 |
| Average True Range (ATR) | 1.32 | 18.81 |
| MACD | 0.03 | 0.90 |
| Stochastic Oscillator | 57.69 | 51.05 |
Price Performance
Historical ComparisonAbout ARMK Aramark
Aramark, founded in 1936 and headquartered in Philadelphia, Pennsylvania, operates as a food service company providing facility management and workplace solutions. The company primarily generates revenue from its North American food and support services segment, serving clients such as schools, healthcare facilities, and entertainment venues.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.